{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:57Z","timestamp":1791251817926,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.neuropharm.2010.10.020","type":"journal-article","created":{"date-parts":[[2010,10,29]],"date-time":"2010-10-29T04:24:38Z","timestamp":1288326278000},"page":"1042-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["The rise of a new GABA pharmacology"],"prefix":"10.1016","volume":"60","author":[{"given":"Hanns","family":"M\u00f6hler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2010.10.020_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bjp.0706056","article-title":"Anxiogenic properties of an inverse agonist selective for \u03b13 subunit-containing GABAA receptors","volume":"144","author":"Atack","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023, an agonist selective for \u03b12- and \u03b13-containing GABAA receptors, is a non-sedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib111","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuropharm.2006.04.018","article-title":"L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors","volume":"51","author":"Atack","year":"2006","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/jpet.109.157636","article-title":"In vitro and in vivo properties of MRK-016, a GABAA receptor alpha5 subtype-selective inverse agonist","volume":"331","author":"Atack","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib6","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1073\/pnas.97.5.2314","article-title":"Imidazenil prevention of alprazolam-induced acquisition deficit in Patas monkeys is devoid of tolerance","volume":"97","author":"Auta","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-008-1357-7","article-title":"RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors","volume":"202","author":"Ballard","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0031-6997(24)01363-2","article-title":"Subtype of \u03b3-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function","volume":"50","author":"Barnard","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABA(A) receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib10","series-title":"Le\u00e7ons sur les effects de substances toxiques et m\u00e9dicamenteuses","author":"Bernard","year":"1857"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib11","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1523\/JNEUROSCI.23-34-10934.2003","article-title":"Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns","volume":"23","author":"Bianchi","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib12","series-title":"Dementia praecox oder Gruppe der Schizophrenien","author":"Bleuler","year":"1911"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1126\/science.6281892","article-title":"Interaction of convulsive ligands with benzodiazepine receptors","volume":"216","author":"Braestrup","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib14","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1073\/pnas.89.22.10598","article-title":"Diazepam-binding inhibitor (DBI)-processing products, acting at the mitochondrial DBI receptor, mediate adrenocorticotropic hormone-induced steroidogenesis in rat adrenal gland","volume":"89","author":"Cavallaro","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib15","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1021\/jm040863t","article-title":"An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties","volume":"47","author":"Chambers","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib16","doi-asserted-by":"crossref","first-page":"19878","DOI":"10.1073\/pnas.0609440103","article-title":"Impairments in frontal cortical \u03b3-synchrony and cognitive control in schizophrenia","volume":"103","author":"Cho","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib17","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","article-title":"Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the \u03b15 subunit of the GABAA receptor","volume":"22","author":"Collinson","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib18","first-page":"531","article-title":"Molecular mechanisms in the receptor action of benzodiazepines","volume":"vol. 19","author":"Costa","year":"1979"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0024-3205(91)90440-M","article-title":"Diazepam binding inhibitor (DBI): a peptide with multiple biological actions","volume":"49","author":"Costa","year":"1991","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib20","first-page":"192","article-title":"Benzodiazepines on trial: a research strategy","volume":"17","author":"Costa","year":"1996","journal-title":"TIPS"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib21","series-title":"Possible Involvement of GABA in the Central Actions of Benzodiazepines","first-page":"113","article-title":"Evidence for the involvement of GABA in the action of benzodiazepines: studies on rat cerebellum","volume":"14","author":"Costa","year":"1975"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1192\/bjp.133.3.239","article-title":"Molecular mechanisms mediating the action of benzodiazepines on GABA receptors","volume":"133","author":"Costa","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib23","series-title":"The Benzodiazepines: From Molecular Biology to Clinical Practice","first-page":"117","article-title":"GABA-benzodiazepine interactions","author":"Costa","year":"1983"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib112","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/80553","article-title":"Resolving differences in GABAA receptor mutant mouse studies","volume":"3","author":"Crestani","year":"2000","journal-title":"Nat. Neurosci"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib24","doi-asserted-by":"crossref","first-page":"8980","DOI":"10.1073\/pnas.142288699","article-title":"Trace fear conditioning involves hippocampal \u03b15 GABAA receptors","volume":"99","author":"Crestani","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1520-6769(199911\/12)25:3<139::AID-NRC3>3.0.CO;2-W","article-title":"Zaleplon diaplays a selecitvity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines","volume":"25","author":"D\u00e4mgen","year":"1999","journal-title":"Neurosci. Res. Commun."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1124\/jpet.105.092320","article-title":"An inverse agonist selective for \u03b15 subunit containing GABAA receptor enhances cognition","volume":"316","author":"Dawson","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib27","first-page":"72","article-title":"Bretazenil: clinical experience","volume":"3","author":"Delini-Stula","year":"1992","journal-title":"Neurosci. Facts"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0022-3956(96)00003-9","article-title":"Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in schizophrenia \u2013 a study group report","volume":"30","author":"Delini-Stula","year":"1996","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib29","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of alpha3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"25","author":"Dias","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib30","series-title":"The Physiology of Synapses","first-page":"220","article-title":"Presynaptic inhibition","author":"Eccles","year":"1964"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0006-8993(75)90243-7","article-title":"Properties of \u03b3-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions","volume":"100","author":"Enna","year":"1975","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0022-3565(25)11126-9","article-title":"Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies","volume":"261","author":"Facklam","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib33","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/nature08928","article-title":"Control of cortical GABA circuity development by Nrg1 and ErbB4 signalling","volume":"464","author":"Fazzari","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.063487","article-title":"In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative\u2013hypnotic","volume":"311","author":"Foster","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cne.903590111","article-title":"GABA-A receptor heterogeneity in the adult brain: differential regional and cellular distribution of seven major subunits","volume":"359","author":"Fritschy","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib36","series-title":"Excitatory Inhibitory Balance: Synapses, Circuits and Systems Plasticity","first-page":"215","article-title":"GABAA receptor subtypes with special reference to memory function and neurological disorders","author":"Fritschy","year":"2004"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-3565(25)38411-9","article-title":"Imidazenil: a new partial positive allosteric modulator of GABA action at GABAA receptors","volume":"266","author":"Giusti","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib38","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1523\/JNEUROSCI.4751-07.2008","article-title":"Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?","volume":"28","author":"Glykys","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib39","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.83.19.7547","article-title":"Cloning and expression of cDNA for human diazepam-binding inhibitor, a natural ligand of an allosteric regulatory site of the \u03b3-aminobutyric acid type A receptor","volume":"83","author":"Gray","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1527-3458.2003.tb00241.x","article-title":"SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms","volume":"9","author":"Griebel","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib41","series-title":"Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications","article-title":"DBI processing: allosteric modulation at different GABA\/benzodiazepine receptor subtypes","author":"Guidotti","year":"1989"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib42","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archpsyc.57.11.1061","article-title":"Decreased in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a post-mortem brain study","volume":"57","author":"Guidotti","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-005-2212-8","article-title":"GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon","volume":"180","author":"Guidotti","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib44","series-title":"The Challenge of Neuropharmacology","first-page":"15","article-title":"Allosteric modulation of the GABAA receptor channel: a mechanism for interaction with a multitude of central nervous system functions","author":"Haefely","year":"1994"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib45","series-title":"Possible Involvement of GABA in the Central Actions of Benzodiazepines","first-page":"131","article-title":"Possible involvement of GABA in the central actions of benzodiazpines","volume":"vol. 14","author":"Haefely","year":"1975"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0165-6147(90)90126-S","article-title":"Novel anxiolytics that act as partial agonists at benzodiazepine receptors","volume":"11","author":"Haefely","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1460-9568.2000.00964.x","article-title":"Cell type and synapse-specific variability in synaptic GABAA receptor occupancy","volume":"12","author":"Hajos","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/290514a0","article-title":"Selective antagonists of benzodiazepines","volume":"290","author":"Hunkeler","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1126\/science.1149381","article-title":"Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operation","volume":"321","author":"Klausberger","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature06493","article-title":"Reversal of pathological pain though specific spinal GABAA receptor subtypes","volume":"451","author":"Knabl","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pain.2008.10.015","article-title":"Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice","volume":"141","author":"Knabl","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib52","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/00001756-200410050-00031","article-title":"Sleep EEG changes after zolpidem in mice","volume":"15","author":"Kopp","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib53","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2004.06.040","article-title":"GABA(A) agonists and partial agonists: THiP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic","volume":"68","author":"Krogsgaard-Larsen","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/jpet.105.084681","article-title":"Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor","volume":"314","author":"Langen","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib57","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/appi.ajp.2008.08030395","article-title":"Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia","volume":"165","author":"Lewis","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib58","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib59","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.918669","article-title":"Demonstration of benzodiazepine receptors in the central nervous system","volume":"198","author":"M\u00f6hler","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib60","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.77.3.1666","article-title":"Benzodiazepine receptor protein identified and visualized in brain tissue by photo affinity labeling","volume":"77","author":"M\u00f6hler","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib61","first-page":"225","article-title":"Pathophysiology and pharmacology of GABAA receptors","volume":"vol. 169","author":"M\u00f6hler","year":"2005"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"M\u00f6hler","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib63","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1042\/BST0371328","article-title":"Role of GABAA receptors in cognition","volume":"37","author":"M\u00f6hler","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib65","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.150.3699.971","article-title":"Pain mechanisms: a new theory","volume":"150","author":"Melzack","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib66","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.108.138859","article-title":"NS11394, a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy","volume":"327","author":"Mirza","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0166-2236(94)90155-4","article-title":"Bridging the cleft at GABA synapses in the brain","volume":"17","author":"Mody","year":"1994","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib68","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.108.144568","article-title":"Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 with diazepam, zolpidem, bretazenil and gaboxadol in rat models of inflammatory and neuropathic pain","volume":"327","author":"Munro","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ab.20032","article-title":"Behavioral profile of L-655 708, a selective ligand for the benzodiazepine site of GABAA receptors which contain the \u03b15 subunit in social encounters between male mice","volume":"30","author":"Navarro","year":"2004","journal-title":"Aggress. Behav."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0024-3205(79)90509-5","article-title":"Some properties of 3H diazepam displacing activity from human urine","volume":"25","author":"Nielsen","year":"1979","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.neuropharm.2007.08.008","article-title":"Blockade of alcohol\u2019s amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inversse agonist","volume":"53","author":"Nutt","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.108.00505","article-title":"International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit composition, pharmacology and function","volume":"60","author":"Olsen","year":"2008","journal-title":"Update. Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib73","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1210\/endo-129-3-1481","article-title":"Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors","volume":"129","author":"Papadopoulos","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib74","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1523\/JNEUROSCI.19-02-00578.1999","article-title":"Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses","volume":"19","author":"Perrais","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib75","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00504702","article-title":"The effect of diazepam on spinal cord activities: possible sites and mechanism of action","volume":"284","author":"Polc","year":"1974","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"Suppl. 11","key":"10.1016\/j.neuropharm.2010.10.020_bib76","first-page":"19","article-title":"Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone","volume":"58","author":"Pollack","year":"1977","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib77","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1073\/pnas.89.8.3620","article-title":"Molecular mechanisms of the partial allosteric modulating effects of bretazenil at \u03b3-amino-butyric acid type A receptor","volume":"89","author":"Puia","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib78","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrn1496","article-title":"Molecular and neuronal substrates for general anaesthetics","volume":"5","author":"Rudolph","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib80","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific \u03b3-aminobutyric acidA receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-6147(00)01646-1","article-title":"GABAA receptor subtypes: dissecting their pharmacological functions","volume":"22","author":"Rudolph","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.1175055","article-title":"Translocator protein (18KD) as target for anxiolytics without benzodiazepine-like side effects","volume":"325","author":"Rupprecht","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.brainres.2008.02.020","article-title":"PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats","volume":"1208","author":"Savic","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib84","first-page":"93","article-title":"Action of diazepam on the spinal cord","volume":"194","author":"Schlosser","year":"1971","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib85","first-page":"20","article-title":"Presynaptic inhibition in the vertebrate central nervous system","volume":"63","author":"Schmidt","year":"1971","journal-title":"Ergeb. Physiol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00535931","article-title":"Die Wirkung von Diazepam auf die pr\u00e4synaptische Hemmung und andere R\u00fcckenmarksreflexe","volume":"258","author":"Schmidt","year":"1967","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(83)90656-8","article-title":"Purified benzodiazepine receptor retains modulation by GABA","volume":"95","author":"Schoch","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/10799898409042549","article-title":"A GABA\/benzodiazepine receptor complex from bovine brain: purification, reconstitution and immunological characterization","volume":"4","author":"Schoch","year":"1984","journal-title":"J. Recept. Res."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/314168a0","article-title":"Co-localization of GABA-A receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies","volume":"314","author":"Schoch","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib90","series-title":"The Brain","first-page":"29","article-title":"The GABA A receptor family: molecular and functional diversity","volume":"vol. 55","author":"Seeburg","year":"1990"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib91","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1016\/S0021-9258(17)39860-5","article-title":"A \u03b3-aminobutyric acid\/benzodiazepine receptor complex from bovine cerebral cortex. Improved purification with preservation of regulatory sites and their interactions","volume":"259","author":"Siegel","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib92","series-title":"GABA Receptor","first-page":"69","article-title":"Subunit composition and structure of GABAA receptor subtypes","author":"Sieghart","year":"2006"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib93","doi-asserted-by":"crossref","first-page":"17288","DOI":"10.1073\/pnas.0406074101","article-title":"Neural synchrony indexes disordered perception and cognition in schizophrenia","volume":"101","author":"Spencer","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib94","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0306-4522(97)00146-2","article-title":"GABA-A receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits","volume":"80","author":"Sperk","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib95","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/266732a0","article-title":"Benzodiazepine receptors in rat brain","volume":"266","author":"Squires","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib96","series-title":"Anxiolytic \u03b2-Carbolines: From Molecular Biology to the Clinic","first-page":"79","article-title":"Abecarnil: a novel anxiolytic with mixed full agonist\/partial agonist properties in animal models of anxiety and sedation","author":"Stephens","year":"1993"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(03)01603-0","article-title":"Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity","volume":"467","author":"Storustovu","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archpsyc.60.2.161","article-title":"Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results","volume":"60","author":"Str\u00f6hle","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0028-3908(71)90083-9","article-title":"Diazepam and presynaptic inhibition","volume":"10","author":"Stratten","year":"1971","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/274383a0","article-title":"GABAergic modulation of benzodiazepine binding site sensitivity","volume":"274","author":"Tallman","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biopsych.2008.01.021","article-title":"In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha2\/alpha3\/alpha5 subtype selective gamma-aminobutyric\u00a0acid-A partial agonist","volume":"64","author":"Van Laere","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib103","doi-asserted-by":"crossref","first-page":"15218","DOI":"10.1073\/pnas.2435171100","article-title":"Ethanol enhances alpha 4 beta3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentration known to affect humans","volume":"100","author":"Wallner","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib104","first-page":"648","article-title":"The GABAA receptor gene family: new opportunities for drug development","volume":"6","author":"Whiting","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib105","series-title":"GABA in the Nervous System: the View at Fifty Years","first-page":"113","article-title":"Pharmacologic subtypes of GABAA receptors based on subunit composition","author":"Whiting","year":"2000"},{"key":"10.1016\/j.neuropharm.2010.10.020_bib106","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/j.1460-9568.2004.03642.x","article-title":"GABA receptors containing the \u03b15 subunit mediate the trance effect in aversive and appetitive conditioning and extinction of conditioned fear","volume":"20","author":"Yee","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib107","doi-asserted-by":"crossref","first-page":"17154","DOI":"10.1073\/pnas.0508752102","article-title":"A schizophrenia-related sensorimotor deficit links \u03b13-containing GABAA receptors to a dopamine hyperfunction","volume":"102","author":"Yee","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib108","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1073\/pnas.70.10.2832","article-title":"Strychnine binding associated with glycine receptors of the central nervous system","volume":"70","author":"Young","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.intimp.2007.07.009","article-title":"Loss of glycinergic and GABAergic inhibition in chronic pain","volume":"8","author":"Zeilhofer","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2010.10.020_bib110","first-page":"397","article-title":"GABAergic analgesia: new insights from mutant mice and subtype-selective agonists","volume":"30","author":"Zeilhofer","year":"2009","journal-title":"TIPS"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081000290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081000290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:43:01Z","timestamp":1758436981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081000290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":110,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S002839081000290X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.10.020","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rise of a new GABA pharmacology","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}